HomeUSAFlagship Pioneering Raises $3.6 Billion to Accelerate Innovations Across Human Health and...

Flagship Pioneering Raises $3.6 Billion to Accelerate Innovations Across Human Health and Sustainability

Flagship Pioneering

Flagship Pioneering, a Cambridge, MA-based bioplatform innovation company, announced it has expanded its capital base by $3.6 Billion to support the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence.

Flagship has raised $2.6 Billion into Fund VIII, in addition to side funds that include sector-specific strategic partnerships totaling $1 Billion. This brought the total capital raised by Flagship into its funds since 2021 to $6.4 Billion.

With its latest raise, Flagship is now operating with an aggregate capital pool of $10.9 Billion, with $14 Billion of assets under management.

The firm’s approach to science and to biotech platforms has led to several novel partnerships within the pharmaceutical industry and beyond. In the past year, Flagship announced strategic partnerships with Pfizer, Samsung, and Thermo Fisher Scientific, in addition to reaching partnership milestones with Novo Nordisk.

Flagship’s expansion into APAC, focused on serving Singapore, Japan and South Korea, will allow the firm to accelerate the growth and scaling of its companies through strategic partnerships across industry, academia, and healthcare systems in the region.

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value.